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Systems biology studies the structure and dynamics of biological systems using
mathematical approaches. Bottom-up approaches create models from prior knowledge
but usually cannot cope with uncertainty, whereas top-down approaches infer models
directly from data using statistical methods but mostly neglect valuable known
information from former studies. Here, we want to present a workflow that includes
prior knowledge while allowing for uncertainty in the modeling process. We build not
one but all possible models that arise from the uncertainty using logical modeling and
subsequently filter for those models in agreement with data in a top-down manner. This
approach enables us to investigate new andmore complex biological research questions,
however, the encoding in such a framework is often not obvious and thus not easily
accessible for researcher from life sciences. To mitigate this problem, we formulate a
pipeline with specific templates to address some research questions common in signaling
network analysis. To illustrate the potential of this approach, we applied the pipeline to
growth factor signaling processes in two renal cancer cell lines. These two cell lines
originate from similar tissue, but surprisingly showed a very different behavior toward
the cancer drug Sorafenib. Thus our aim was to explore differences between these cell
lines regarding three sources of uncertainty in one analysis: possible targets of Sorafenib,
crosstalk between involved pathways, and the effect of a mutation in mammalian target
of Rapamycin (mTOR) in one of the cell lines. We were able to show that the model
pools from the cell lines are disjoint, thus the discrepancies in behavior originate from
differences in the cellular wiring. Also the mutation in mTOR is not affecting its activity in
the pathway. The results on Sorafenib, while not fully clarifying the mechanisms involved,
illustrate the potential of this analysis for generating new hypotheses.
Keywords: systems biology, logical modeling, model checking, constraint based modeling, signaling pathways
1. INTRODUCTION
Logical modeling has been shown to be a powerful tool for representing and analyzing biological
systems (Saez-Rodriguez et al., 2007; Wang et al., 2012; Grieco et al., 2013). The main advantage
in comparison to the standard modeling formalism in systems biology, Ordinary Differential
Equations (ODE) modeling, is the low number of parameters, therefore logical models are mainly
used to build large models that would be too complex for ODEs (Abou-Jaoudé et al., 2016). These
models are usually built in a bottom-up manner, which means all available information about the
Thobe et al. Evaluating Uncertainty Using Model Pools
system is gathered and validated on new data (Figure 1B). A
main issue when building these models is that uncertainty cannot
be included into the model, e.g., if an influence between two
components is controversial in the literature. Since only one
model is created, the modeler needs to make an assumption
neglecting the uncertain information. A second popular strategy
for modeling is to use a top-down approach where the model is
inferred directly from data, but here prior knowledge about the
system is neglected (De Smet and Marchal, 2010).
As a consequence, alternative approaches have become more
popular, where uncertainty is included into the modeling process
by either building more than onemodel or by adapting the model
through training. For exploring a wide range of models that is
able to show a certain dynamical behavior, called family or pool
of models, there are different methods available. The group of
Saez-Rodriguez et al. developed a software CellNOptR to train a
candidate model to data, accounting for topological uncertainties
(Terfve et al., 2012). The output is a family of models selected for
an optimality criterion, but cannot guarantee completeness due
to stochastic search. The software caspo by the group of Siegel
et al. uses Answer Set Programming to infer a family of logical
models from experimental data based on optimization, where a
tolerance accounts for experimental noise. The resulting family
of models then represents all optimal models that reproduce the
data and the software provides several analysis tools to explore
properties of the models, such as classification for input/output
behavior or experimental design (Videla et al., 2017). A similar
method using time series data for inferring a model pool showed
to be more precise than caspo (Ostrowski et al., 2016). A different
approach was developed by our group, where uncertainty in
parameters of the model, such as an uncertain sign of an edge,
is encoded into the model definition (Klarner et al., 2012)
and all possible models that arise from this uncertainty are
enumerated. Subsequently the models are tested for satisfiability
for data without an optimality criterion (Figure 1A), which was
implemented using efficient formal verification techniques in
Tremppi (Streck et al., 2015) and in TomClass (Klarner, 2014).
Even though we employ the software from our group for the
analysis in this paper, one could apply different software along
the pipeline for building the model pool or analyzing it.
While computing model pools and testing them for data
sets is computationally challenging, the analysis of potentially
hundreds or thousands of models is not straight-forward in terms
FIGURE 1 | Workflow for our modeling approach in comparison to traditional modeling process. (A) First a generic model pool is created from all available information
including uncertainty. Then, the pool is filtered for data to find specific subpools, which can be analyzed for new information. (B) The traditional workflow creates one
model based on assumption, estimates parameter values by fitting the model to data and validates the model on additional data.
of the biological interpretation. Thus we propose a hypothesis-
driven approach for specific biological questions, where the use
of model pools allows us to test multiple hypotheses at the same
time and analyze their interdependencies. Mathematical models
are artificial constructs used to help understanding biological
processes. In order to receive meaningful results from amodeling
study, the biology needs to be transferred into mathematics and
the results need to be interpreted from a biological perspective.
In this paper, we address this task of incorporating biological
information into the formalism by expanding the workflow in
Figure 1 to a four-step pipeline. At first, the process of bottom-up
model building formalizes the biological phenomena into a prior
knowledge network, which we call system initialization. Here,
the regulatory graph and the logical equations are derived from
literature information. Then, the objective formalization includes
the aim of the study into the model setup, e.g., by adding extra
components or edges. After generating the model pool, the top-
down filtering process uses biological data that is not restricted to
be of a specific type such as steady-state or input-output behavior.
However, it requires a data formalization step. Finally, the pool
analysis examines the specific pool for new biological insight.
In previous work, we presented parts of this pipeline, i.e.
the objective of investigating crosstalk between two signaling
pathways in Thobe et al. (2014), as well as challenges for data
discretization and analysis in Streck et al. (2015) in context
of a specific software. Here, we generalize and expand this
pipeline by two additional objectives and analysis methods.
Especially in the context of signaling processes in cancer cells,
the identification of driver mutations is of great interest (Bozic
et al., 2010), thus one aim of our framework is to identify
driver mutations by a change in the logical function. The
second aim presented is testing the effect of drugs by
introducing them as new inputs to the system. Analyzing
pools containing possibly hundreds or thousands of models is
challenging. Here, we show a classification analysis to structure
the resulting models toward interesting features, as well as
extracting minimal mechanisms for a more detailed view on the
models.
We apply this pipeline to model two central signaling
processes involved in cancer, the mitogen-activated protein
kinase (MAPK) cascade and the mTOR pathway (Shaw and
Cantley, 2006; Saini et al., 2013), in two renal cancer cell (RCC)
lines. Both cell lines were treated with the Raf-inhibitor Sorafenib
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yet displayed a differential response in terms of apoptosis
induction (Kuznia, 2015). We hypothesized that the difference
between these cell lines might be caused by distinct wiring of
MAPK and mTOR signaling, which were shown to be connected
via crosstalk (Mendoza et al., 2011; Aksamitiene et al., 2012). A
rich dataset of time series measurement of key components in
both pathways was generated using a high-throughput method,
which was the foundation for the complex analysis presented in
this study.
This paper is organized as follows. The Methods section first
gives a brief introduction on the logical modeling framework and
a detailed description on the pipeline we developed. In the Results
section, the application on a signaling network is demonstrated,
where first the model building process with the corresponding
biological background is given, the data processing procedure
is described and the results of the analysis are presented.
Additionally, the biological interpretation is discussed and
future experiments are suggested to wrap up the application
section. Finally, the Discussion section exploits advantages
and shortcomings of the method showing potential future
extensions.
2. METHODS
2.1. Theoretical Background
The formalization of logical modeling for biological systems was
introduced by Kauffman (1969) and further refined by Thomas
(1991), which is the base for our work. However, we expanded
this formalism to incorporate uncertain information leading to
model pools (Klarner, 2014; Thobe et al., 2014, 2017; Streck, 2015;
Streck et al., 2015).
2.1.1. Logical Modeling
The topology of a biological system is defined as a directed
graph R = (V ,E, l), called interaction graph (IG), where the
nodes V = {1, ..., n} represent the components of the system that
are connected by edges e ∈ E ⊆ V × V called interactions,
which represent a regulation of one component by another. The
components adapt discrete values, called activity levels, and we
consider Boolean networks (BN) with two levels assigned to each
component B = {0, 1}, where 0 means inactive and 1 stands
for active. By assigning activity levels to every component of
the network, the state of the system s is defined by s :V →
{0, 1},∀v ∈ V : s(v) ∈ B. Here, the notation of a state is
specified as a sequence in the order ofV . In our approach, we add
information about the nature of a regulation to each interaction
using edge labels l :E→ {+,−,¬+,¬−} (adapted from Klarner,
2014). In application, the labels {+,−} are assigned to edges that
represent well-known information, e.g., textbook knowledge, and
are therefore required to be present in every model, which we
call essential. In contrast, the labels {¬+,¬−} are assigned to
interactions that carry uncertainty, i.e., we not sure whether this
interaction is present or not, which we call optional. However, we
assume that the sign of an edge is known and exclude edges with
unknown or ambivalent sign due to complexity.
Having defined the wiring of the network, the regulation of
a component by its predecessors is defined by a logical function.
The conditions describing when a component becomes active can
be expressed using the logical operators ∨ (OR), ∧ (AND), and
¬ (NOT) in a formula fi for every component v ∈ V consistent
with the edge labels. This means that variables j are literals in f
for component i, if j → i is a possible edge. Then a positive edge
label has to cause an increasing value in the target component at
some point, whereas a negative edge label has to cause a decrease.
For optional edges, the increase or decrease can occur or that
value is constant. However, in case the regulation of a component
is uncertain of a component has optional incoming edges more
than one model can be build from the available information.
Then the set or all logical equations that are consistent with the
edge labels are created and form the so-called model pool. An
example is given in Figure 2.
2.1.2. Dynamical Behavior and Model Checking
In order to compare biological measurements with the dynamic
behavior of the models, we need to define the transition from
one state to another to generate the systems behavior over
discrete time steps. For this aim, different update strategies have
been developed, where some make assumptions on the timing
of events, e.g., in synchronous update all components change
in one transition, and others restrict the ordering of events,
e.g., stochastic updates randomly update a component. Here,
we employ asynchronous update, which is the least restrictive
strategy at the cost of being computationally expensive (Thomas,
1991). In this strategy only one component can change its value
per transition step, which means for fv(s) = ¬sv for a state
s = (s1, . . . , sv, . . . , sn) denote with s
v = (s1, . . . ,¬sv, . . . , sn)
the state which differs from s in the value of the component v.
If no component changes f (s) = s a steady-state of the system is
reached. This update schedule produces every possible trajectory
emerging from a state, thus the dynamics are non-deterministic
which can be visualized in the so-called state transition graph
(STG). Here, the states are the nodes of the graph and the
transitions are edges.
After building the model pool from the available information,
we want to filter those model that are in agreement with observed
experimental data. Depending on the utilized software, either the
data can be implemented as continuous values (e.g., Terfve et al.,
2012) or needs to be discretized. Here, we want to describe two
different kinds of biological data: time-series measurements and
steady state observations. For this aim, we use temporal logics
that are able to describe an ordering or a sequence of events in
time, where computation tree logic (CTL) can cope with non-
deterministic sequences (Clarke et al., 1986) and are therefore
suited to explore the STG. For time-series measurements we
encode a series of states that should exist at some point in the
future and for steady states we encode the state of a component(s)
that should hold for every state in the future. These formulas
are then tested on the STG of the models using model checking.
This process can be computationally expensive, since the state
space exponentially increases with the number of components,
also the number of models can quickly add up to thousands of
models. For this reason, an efficient model checking software
should be employed, e.g., Tremppi (Streck et al., 2015) and
TomClass (Klarner, 2014).
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FIGURE 2 | Model definition to model checking visualized on a toy example. (A) IG with four components, edge labels and the corresponding functions resulting in
model pool of size three in (B). (C) shows time-series measurements for some activity a of B, C, and D, which is discretized by a threshold shown in green. The table
in (D) gives the discretized data for the four time points, which are encoded as CTL formulas in (E), where EF(X) is a CTL operator exists finally. This states that on
some path from an initial state the X holds true at some point. STGs in (F) of the three models in the pool show the process of model checking for the CTL formula
indicated by green states and edges, where the second model is not in agreement with the data.
2.1.2.1. Toy example
In Figure 2, model definition to model checking is visualized
for a toy example. Here, an IG with four components is given,
where the regulation of components A, B, and D is known,
indicated by the edge labels and the corresponding functions.
Component C has an uncertain regulation by component D,
therefore the edge is labeled as not inhibiting and the function
for C is undefined (Figure 2A). The resulting model pool then
contains three different models that arise from the edge label.
The process of temporal encoding of data is shown for time-series
measurements, which is discretized by a threshold and encoded
as CTL formulas, where the CTL operator exists finally is used.
This operator states that the measurements must lie on one path
in the ordering of the measurements in the STG, where there is
no restriction made on how many states are visited in between
the measurements. The CTL language offers more operators that
could be employed depending on the type of data (Klarner et al.,
2012), e.g., reflecting that the measurement frequency was so
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FIGURE 3 | Pipeline for evaluating uncertainty in biological systems. For building the prior knowledge network and defining the uncertainties of the system, the system
initialization and objective formalization is necessary. The filtering process from the generic model pool to the specific model pool requires data formalization and the
interpretation of the final pool is done by pool analysis.
high that one can assume that all qualitative activity changes of
each component have been captured. However, in this paper we
used the most conservative form. Finally, the process of model
checking is visualized in Figure 2F showing that one model is not
in agreement with the data.
2.2. Pipeline for Modeling Uncertain
Systems
Based on the very general workflow in Figure 1, we want to
formalize in more depth how specific biological questions can
be addressed using model pools (Figure 3). In comparison to
the traditional workflow for building and analyzing one model,
there are similarities and differences. The main difference is
that the standard bottom-up approach creates one model to
test a single hypothesis, which is validated using (formalized)
data and subsequently analyzed. Using model pools, the system
initialization and data formalization remains the same, but we
can test multiple hypothesis at the same time. This leads to a
higher complexity in both the formulation of the aim of the study
and the analysis of the model pool for biological information.
To this end, the workflow has been adopted and specified to
address common analysis themes for signaling networks. The
resulting pipeline, shown in Figure 3, contains four steps: system
initialization, objective formalization, data formalization, and
pool analysis.
In the following, we provide a detailed formal description for
the objective formalization and pool analysis. We assume that
for the system initialization, available information is gathered
and classified according to the theory presented in Section 2.1
for components, edges, and edge labels. Moreover, insight on
regulations of components can be included by defining logical
functions. This first step results in the prior knowledge network
(PKN), which forms the starting point for our analysis (Saez-
Rodriguez et al., 2011).
2.2.1. Objective Formalization
In the second step of our pipeline, we want to include the
objective of the analysis into the PKN. In a simple setup, this
could mean adding optional edges as hypotheses, but there are
also more complex aims that require changes in the PKN. The
first objective we identified, was to examine crosstalk between
two pathways while preserving the dynamical properties of each
pathway, presented in Thobe et al. (2014). Here, we want to
present two different objectives: Finding driver mutations and
drug testing.
2.2.1.1. Finding driver mutations
Cancer cells often accumulate mutations that are distinguished
as either driver or passenger mutations. A lot of effort has been
made to identify the driver mutations, since they are assumed
to be a major cause for cancerous behavior (Greenman et al.,
2007; Bozic et al., 2010). This abnormal behavior is due to the
fact that the mutations affect the protein they are encoding
in quality, changed sequence of the protein, or quantity, such
as overexpression or knock-out of a gene. These effects cause
changes in the regulatory network leading to an insensitivity
of the component from its regulators, e.g., constantly active
receptors. We aim to identify these changes in the regulation of
a component in our approach, which we were able to confirm in
previous work (Streck et al., 2016).
We account for mutations in components of a model
with uncertain effect by setting the respective incoming and
outgoing edges to optional even if these connections are textbook
knowledge. In case more detailed information on the effect of the
mutation is available, only a subset of edges can be set to optional.
Formally, the network R = (V ,E, l) is defined as in Section 2.1,
where the set of mutated components is given by Vm ⊆ V with
edges Em = {(u, v) ∈ E | v ∈ Vm ∨ u ∈ Vm}. The labeling lm of
edges in Em is set to:
lm(u, v) =
{
¬+ if (u, v) ∈ Em and l(u, v) = −
¬− if (u, v) ∈ Em and l(u, v) = +
.
Thus, the affected edges are allowed to either stay the same
or lose their function in the resulting model pool. If in the
specific pool an incoming edge is not observable in any model,
the mutated component becomes independent from its inputs
and the function of the component can either be set to 0 or 1
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indicating a loss-of-function or constitutively active mutation,
respectively. A lost outgoing edge of the mutated component can
indicate that the mutation affected the protein structure which
can result in a dysfunctional protein. However, we do not account
for gain-of-function mutations in this set-up, since this would
require to add new edges to the model or change the sign of an
edge. This would strongly increase the complexity of the study
and should be addressed only based on suggestive data in a case
by case way, which is no fit for this general set-up.
2.2.1.2. Drug testing
This objective aims to test qualitative effects of drugs on
pools of models, without knowledge of the “true” network.
Especially in cancer research, combinatorial therapies have
become increasingly popular to enhance efficiency and overcome
resistances (Ho et al., 2012; Manchado et al., 2016). Since we
cannot represent concentrations or generally quantitative effects,
the questions we want to address can be formulated as: where do
we have to interrupt the signaling process to achieve a certain
outcome. A similar study was done by Klinger et al. where
they predicted the model structure and treatment quantitatively,
however, the predictions resulting from the study were qualitative
nature (Klinger et al., 2013).
For this approach, we introduce drugs as new components
to the PKN and connect them with an inhibitory edge to their
target, since they are supposed to suppress the activity of their
target. For the network R′ = (V ′,E′, l′) with f ′ as given logical
equations, an extended set of components V is given by V ′ ∪ VD
where vD ∈ VD is a set of drug components. The interactions
of the network are given by E = E′ ∪ ED where new edges
ED are added, which contain an edge for self-activation for each
new component to create the drug as input and an inhibitory
edge from vD to its target u, since the drug suppresses the
activity of its target. Similarly, the set of labels is composed of
the labels of the original network and the additional labels for the
drug components, where known interactions are labeled with an
essential label and uncertain effects with an optional label.
We can also include available information about the drug’s
mode of action into the logical function of its target. Usually
drugs are selected to have a dominant influence on their target,
for example through binding or modification it fails to interact
with its former regulators. In case the logical equation of a drug
target is known, we can directly translate this dominant effect on
the target u in a new logical equation:
fu = f
′
u ∧ ¬vD.
However, if detailed information about the biochemical
properties of the drug on the target and other regulators is
missing, the logical equation of the target is not defined and all
possible regulations are generated in the pool.
2.2.2. Pool Analysis
After building the generic model pool from the PKN, this pool
of models gets reduced for those models that are valid for data.
Depending on the software, the data needs to be processed to
apply it to logical models usually by discretization (Dimitrova
et al., 2010; Gallo et al., 2015). As a result, we receive one or
more specific model pools that need to be analyzed. For this
aim, different kinds of analysis tools can be employed depending
on the aim and the size of the resulting model pool such as
statistical analysis (Thobe et al., 2014; Streck et al., 2016) or
optimization (Terfve et al., 2012; Videla et al., 2017). Here, we
want to present an analysis approach that allows a closer look at
classes of models as well as single models.
2.2.2.1. Classification
Depending on the study, this pipeline can lead to specific model
pools that contain too many models to analyze them by hand.
This analysis step aims to get an intuition for commonalities
or differences of models within the model pool, with respect to
properties of interest. For this goal, properties such as validity for
data or presence of an optional edge can be annotated to each
model by e.g., using a database. Then, we can group sets ofmodels
into classes and compare them according to these properties to
find difference between sets of models, for example we could
observe that two optional edges are present in the model pool
but occur mutually exclusive.
Here, the model pool is stored in a database and SQL queries
are used to classify the models. For the queries, properties or a
list of properties can be used as a classifier and are defined in the
parameter Classes. Also we can restrict the pool to a subpool
using the parameter Restriction, where we can select models
for their property, e.g., only including all models that carry
an optional edge. Mathematically, the analysis finds subsets of
models that have a non-empty intersection and computes the
cardinalities of these sets (Klarner, 2014). For this aim, an SQL
query is generated using statements of the form:
SELECT DISTINCT Classes FROM models WHERE Restriction,
where SELECT DISTINCT computes all combinations of
labels, i.e., subsets, of the selected Classes in the database
models, possibly restricted using WHERE. Additionally, COUNT
is used to determine the cardinality of each subset, i.e., the
number of models in a class later denoted as size of a class. It
is possible that classes are empty if there exists no model in the
pool with a particular label combination.
2.2.2.2. Minimal models
While the classification gives a broad overview on themodel pool,
we also want to look at single models in the pool. The selection
of models can be motivated by the objective and the biological
background, by the classification analysis or by general criteria
such as minimality. The criterion minimal can be interpreted in
different ways: structural minimality in terms of number of edges,
functional minimality in terms of shortest logical equations,
or models that require least number of transitions to fulfill
data. Each minimality can be interesting to regard separately or
in combination. Structural minimality is a common biological
assumption, where the system is assumed to have evolved in an
energetically optimal way and is therefore sparse. Along with the
number of interaction partners, the complexity of the regulation
formulated as logical function can be assumed to be rather
simple. Previous studies often used fixed rules for creating these
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functions, such as activation- inhibition function (Martin et al.,
2007), or optimized for short logical function (Videla et al., 2017).
Technically, this analysis counteracts the problem of
overfitting. In general, the more degrees of freedom are available
to a system, the easier is can produce various dynamics, thus our
method has a bias toward building dense models. It is therefore
beneficial to identify minimal structures or functions.
2.2.2.3. Interpretation of analysis results
Finally, the results from the analysis need to be transferred
and interpreted to gain biological insight, which is not straight
forward. Since the models are qualitative, the level of abstraction
is high and the fact that we are looking at pools of models
increases the complexity. However, by specifying clear objectives
and predefined analysis options, the pipeline guides the modeling
process and can deliver valuable information for experimental
design or further modeling steps (Streck et al., 2015; Thobe et al.,
2017).
3. RESULTS
3.1. Application on Growth Factor
Signaling in Renal Cancer Cells
After presenting a pipeline to build model pools for different
objectives and analysis options, we wanted to apply this pipeline
to model growth factor signaling in two renal cancer cell lines,
MZ1851RC and MZ1257RC. Motivation for this study was an
observation that cell line MZ1851RC showed apoptosis after
being treated with the drug Sorafenib while MZ1257RC seemed
to be resistant (Kuznia, 2015). Sorafenib was developed to inhibit
pathways controlling proliferation and cell survival and was
shown to have anti tumor activity in colon, breast, and non-
small lung cancer (Wilhelm et al., 2004; Gadaleta-Caldarola
et al., 2015). The multikinase inhibitor Sorafenib was designed to
suppress activity of Raf kinases in the MAPK pathway (Liu et al.,
2006), however, it also affects a wide variety of receptor tyrosine
kinases (RTKs) (Wilhelm et al., 2004). Very recently, Sorafenib
was shown to inhibit the IGFR in vitro (Yaktapour et al., 2013),
which indicates that Raf comprises an uncertain drug target in
the renal cancer cell lines tested with our approach.
A second uncertainty was introduced by a mutation in the
component mTOR in cell line MZ1851RC, but the effect of
this mutation is unknown (Kuznia, 2015). A third uncertainty
was caused by crosstalk between the MAPK pathway and PI3K
signaling (Figure 4A), which was shown to compensate drugging
of one of the pathways (Mendoza et al., 2011; Aksamitiene et al.,
2012). Thus, the overall aim of this study was to clarify if the
deviating behaviors are caused by differences the cellular wiring,
which effect the mutation has and which targets Sorafenib is
affecting.
3.2. Objective Formalization
The objective of this study splits into three different aims:
investigating crosstalk between MAPK and PI3K pathways,
finding the target for Sorafenib, and clarifying the effect of the
mutation in mTOR. The PKN was extracted from literature,
where the MAPK model was based on work by Kholodenko
(2000) and the PI3K model was adapted from Courtney et al.
(2010), also it is an adaption from a previous study (Thobe
et al., 2014). For investigating the wiring between MAPK
and PI3K pathway, candidate crosstalks were added. In detail,
strongly activated MAPK signaling was found to cross-activate
PI3K signaling, i.e., Erk was observed to phosphorylate Tsc2
suppressing it and Erk was also shown to phosphorylate Raptor,
where both crosstalks activate mTORC1 signaling similarly to
Akt (Roux et al., 2004; Winter et al., 2011). For simplicity,
we summarized this effect to one crosstalk. Moreover, a cross-
activation of EGFR on PI3K through Ras was shown, which is
downstream of EGFR and upstream of Raf (Wong et al., 2010).
A study of Will et al. found that PI3K inhibition, but not Akt
inhibition, causes rapid decrease in wild type Ras activity and in
Raf/Mek/Erk signaling concluding that PI3K cross-activates the
MAPK cascade (Will et al., 2014). For the PKN, the crosstalk
edges were labeled as optional edges and the edges within a
pathway were assumed to be essential, shown in Figure 4B.
In order to test the effect of Sorafenib, it was added as
additional input to the system as well as optional edges to possible
targets: Raf, EGFR, and IGFR. Note that EGFR as Sorafenib target
is a hypothesis and not based on experimental data. Moreover,
one cell line, MZ1851RC carries a mutation in mTOR with
unknown effect for mTORC1, thus the outgoing edge to IGFR
was set to optional. A full list of optional edges in given in
Figure 4D, also for some components the logical function can
be set, since they only have one regulator (Figure 4C). All other
components have undefined logical functions, which gives rise to
the generic model pool.
Moreover, components that were neither measured nor
perturbed were excluded from the model to reduce the
complexity. For example, Mek and Tsc were not considered in
the model, since both were lined up in a cascade as components
with single input and output, thus deleting them does not pose
problems for the model dynamics.
3.3. Data Formalization
3.3.1. Experiments Show Differential Behavior of Cell
Lines
For our investigation, we used two different data sets: Western
blot measurements of mTORC1 activity over time and a high
throughput assay both published in Kuznia (2015). In the western
blot measurements, the activity of mTORC1 was measured by its
targets p70S6K (S6K) and S6RP in MZ1257RC and MZ1851RC
cells. Here, the cells were either treated with DMSO or Sorafenib
and the phosphorylation of the mTORC1 targets was measured
over time. Regarding the measurements until 12 h, MZ1257RC
cells showed a significant decrease in phosphorylation levels
for S6K and S6RP. However, MZ1851RC cells only showed a
reduction in S6RP phosphorylation for later time points, but the
phosphorylation of S6K remained high. The 24 h time point
is not considered, since we are only interested in signaling
effects and this measurement is likely to be influenced by
transcriptional effects. S6K was used as the read-out for the
mTORC1 activity in the formal encoding of theWestern blot data
as CTL formulas WB.DMSO, WB1257Sora and WB1851Sora
in the Table 1. Here, both cell lines show active mTORC1 for
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FIGURE 4 | Model building of growth factor signaling processes (A) Scheme of MAPK cascade and PI3K signaling. (B) Interaction graph of the MAPK (left hand side)
and PI3K (right hand side) model marked with solid lines and optional influence of Sorafenib and crosstalk marked with dashed lines. (C) Predefined logical rules for
regulations of components without optional incoming edges. (D) List of optional edges added to the network with references.
DMSO treatment throughout the measurements, thus a steady
state was assumed and encoded in the CTL formula accordingly.
For Sorafenib treatment, cell line MZ1257RC shows a steady
state with decreased S6K phosphorylation, therefore mTORC1
was set to 0. In contrast, cell line MZ1851RC has stable S6K
phosphorylation, thus mTORC1 was set to 1.
After observing differences in the activity of mTORC1 in
the Western blots toward Sorafenib treatment, we wanted to
investigate where the differences in the upstream regulation
of mTORC1 originate from. For this aim, a high throughput
approach using the Bio-Plex R© system was applied (Kuznia,
2015). Here, the cells were unstimulated and not starved but
treated with Sorafenib or DMSO and measured at different time
points over a total period of 36 h in two experiments. In detail, the
activity of the PI3K/mTORC1 signaling pathway was measured
by the phosphorylation of Akt, and p70S6K as well as the MAPK
activity was determined through the phosphorylation of Erk.
Moreover, the receptors EGFR, and IGFR were included into the
experiment, since we were interested whether the receptors are
targeted by Sorafenib and to account for the feedback processes.
For the complete dataset see Kuznia (2015), processed data is
listed in the Supplementary Table 1.
3.3.2. Discretization of Time Series Data
In order to fit the models in to pool to the time series
measurements, the data needs to be discretized. The choice of
discretization method is influenced by the kind of data acquired
and the experimental method used, for example with large data
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TABLE 1 | Filtering model pool using model checking.
CTL formula
WB.DMSO: EF(AG(mTORC1=1)) IS:Sora=0
WB1257Sora: EF(AG(mTORC1=0)) IS:Sora=1
WB1851Sora: EF(AG(mTORC1=1)) IS:Sora=1
Bp1851Sora: EF(mTor=1&Akt=0&EGFR=0&Erk=0&IGFR=1&EF(mTor=1&Akt=1&
EGFR=1&Erk=1&IGFR=1&EF(mTor=0&Akt=0&EGFR=0&Erk=0&
IGFR=1))) IS:Sora=1
Bp1851DMSO: EF(mTor=1&Akt=1&EGFR=1&Erk=1&IGFR=1&EF(mTor=1&Akt=1&
EGFR=1&Erk=1&IGFR=0&EF(mTor=1&Akt=0&EGFR=1&Erk=1&
IGFR=0&EF(mTor=0&Akt=0&EGFR=0&Erk=0&IGFR=0)))) IS:Sora=0
Bp1851Sora2: EF(mTor=1&Akt=1&EGFR=1&Erk=1&IGFR=1&EF(mTor=0&Akt=1&
EGFR=1&Erk=1&IGFR=1&EF(mTor=1&Akt=1&EGFR=1&Erk=1&
IGFR=0&EF(mTor=1&Akt=0&EGFR=0&Erk=0&IGFR=0&EF(mTor=0&
Akt=0&EGFR=1&Erk=1&IGFR=0&EF(mTor=1&Akt=0&EGFR=1&Erk=1&
IGFR=1)))))) IS:Sora=1
Bp1851DMSO2: EF(mTor=1&Akt=1&EGFR=1&Erk=1&IGFR=0&EF(mTor=0&Akt=1&
EGFR=0&Erk=1&IGFR=0&EF(mTor=0&Akt=0&EGFR=0&Erk=1&
IGFR=0&EF(mTor=1&Akt=1&EGFR=1&Erk=1&IGFR=0&EF(mTor=0&
Akt=0&EGFR=0&Erk=0&IGFR=0&EF(mTor=0&Akt=0&EGFR=1&Erk=1&
IGFR=0&EF(mTor=1&Akt=1&EGFR=1&Erk=1&IGFR=0)))))))
IS:Sora=0
Bp1257Sora: EF(mTor=1&Akt=1&EGFR=1&Erk=1&EF(mTor=0&Akt=0&EGFR=0&
Erk=0&EF(mTor=0&Akt=0&EGFR=1&Erk=0&EF(mTor=1&Akt=1&
EGFR=1&Erk=1&EF(mTor=0&Akt=0&EGFR=1&Erk=0&EF(mTor=1&
Akt=0&EGFR=1&Erk=1)))))) IS:Sora=1
Bp1257DMSO: EF(Delta=0&mTor=1&Akt=1&EGFR=1&Erk=1) IS:Sora=0
Bp1257Sora2: EF(mTor=0&Akt=0&EGFR=0&Erk=0&EF(mTor=0&Akt=1&EGFR=0&
Erk=0&EF(mTor=1&Akt=1&EGFR=1&Erk=1&EF(mTor=1&Akt=1&
EGFR=1&Erk=0&EF(mTor=1&Akt=0&EGFR=1&Erk=1&EF(mTor=1&
Akt=1&EGFR=1&Erk=1)))))) IS:Sora=1
Bp1257DMSO2: EF(mTor=1&Akt=0&EGFR=1&Erk=1&EF(mTor=1&Akt=0&EGFR=1&
Erk=0&EF(mTor=1&Akt=1&EGFR=1&Erk=1&EF(mTor=0&Akt=0&
EGFR=0&Erk=0&EF(mTor=1&Akt=1&EGFR=1&Erk=1))))) IS:Sora=0
CTL formulas derived from Western blot and Bio-Plex® experiments. For denoting the CTL formulas, the following semantics are used: EF(X): is a CTL operator exists finally. This
states that on some path from an initial state the X holds true at some point. AG(X): is a CTL operator all globally. This states that X has to hold for all future states, i.e., X is in a steady
state. v=b: where v ∈ V,b ∈ B states that value of a component v is set to b. IS: declares the initial state and is a list of boolean constraints on the values of the components. A state
is considered initial, if all the constraints are satisfied.
sets statistical methods provide good results, but with small data
sets the choice is more difficult (Dimitrova et al., 2010). Here, we
opted to show a simple approach by using the arithmetic mean as
threshold. More specifically, the data was discretized by defining
for each experiment e and component v, a threshold
θev =
∑
t
∑
x mevtx
|t||x|
where, mevtx is the measured activity of component v in the
experiment e with treatment x. The total number of time points
is |t| and the total number of treatments is |x|.
Since the cells were cultivated and treated in parallel, the
phosphorylated levels for both treatments were expected to
be comparable. Thus, the threshold for e.g., Erk is the same
mean value under both Sorafenib and DMSO treatment within
each cell line for each experiment. Moreover, the standard
deviation for each component was calculated in order to avoid
the problem of discretizing a component that does not change
over time. By looking at small standard deviations relative to the
mean, IGFR measurements for MZ1257RC in both experiments
were identified as problematic (see Supplementary Table 1).
Comparing the IGFR levels between the cell lines, we decided to
exclude this data.
Since we are interested in the signaling processes, only
measurements until 8 h were included. The resulting CTL
formulas are listed in Table 1, where all Bioplex measurements
were encoded as transient states, due to the fact that they
changed throughout the 8 h of measurement. An exception is the
data set Bp1257DMSO, which was encoded as steady state (see
Supplementary Table 1MZ1257RC-DMSO Exp1). Note that the
discretization of data is not always straight-forward, thus we
excluded data which was problematic mathematically (such as
IGFR) or had poor quality in the measurements.
3.3.2.1. Robustness of results
As a basic test of robustness with respect to the discretization
method being used, we additionally performed a discretization by
median instead of mean value. This change in the discretization
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TABLE 2 | Number of models consistent with CTL formulas.
CTL formula Pool size
(A)
WB.DMSO 15,026
WB1851Sora 5,902
Bp1851Sora 10,080
Bp1851DMSO 12,474
Bp1851Sora2 5,632
Bp1851DMSO2 7,216
Rp.1851 293
(B)
WB.DMSO 15,026
WB1257Sora 15,026
Bp1257Sora 9,984
Bp1257DMSO 12,096
Bp1257Sora2 12,393
Bp1257DMSO2 10,032
Rp.1257 1017
Filtering for CTL formulas gives pool sizes as the number of models in agreement. Rp.1851
and Rp.1257 are the cell line specific pools as the intersection of the data sets shown in
(A,B), respectively.
threshold had a negligible effect on both cell lines: 5.7% of the
boolean values changed forMZ1257RC and 7.1% forMZ1851RC.
Furthermore, we repeated the subsequent analysis using the
median discretization, and observed only minor changes in the
size of the model pool for cell line MZ1257RC and no change in
the resulting biological interpretation of that pool.
3.4. Pool Analysis
After deriving the PKN from the literature and including the
objectives of the study, the generic model pool was created. As a
result from combining of all optional edges and logical equations
the pool contains 19,404 models. In order to find biologically
relevant models, the third step of the pipeline generated the
specific pool(s) by filtering the generic pool for those models that
are able to simulate experimentally observed behavior for the two
RCC cell lines.
3.4.1. Cell Line Specific Model Pools
Each CTL formula has a non-zero pool size and is therefore
feasible for our analysis (see Table 2). To determine the cell line
specific models, we calculated the intersection of the different
subpools for cell line MZ1257RC as Rp.1257 and for cell line
MZ1851RC as Rp.1851:
• Rp.1851 = WB.DMSO ∩ WB1851Sora ∩ Bp1851Sora ∩
Bp1851Sora2 ∩ Bp1851DMSO ∩ Bp1851DMSO2
• Rp.1257 = WB.DMSO ∩ WB1257Sora ∩ Bp1257Sora ∩
Bp1257Sora2 ∩ Bp1257DMSO ∩ Bp1257DMSO2
Note that both pools are required to fulfill WB.DMSO, since
this dataset was identical for both cell lines. Although the single
CTL formulas resulted in relatively large pools, containing 5,000–
15,000 models, the intersection for the cell line specific pools
shows a strong reduction with 1017 models for Rp.1257 and
293 models for Rp.1851 (see Table 2). Thus, there exists a cell
line specific pool for each cell line. One interesting question is
whether these cell line specific pools share any models, which we
addressed by calculating the intersection between Rp.1257 and
Rp.1851. The result is an empty set, whichmeans the model pools
Rp.1257 and Rp.1851 are disjoint. In the next step, we wanted to
further characterize and explore these cell line specific pools for
information on crosstalk and Sorafenib targets.
3.4.2. Classification Shows Differences Between Cell
Lines
Besides the sizes of the pools and the information about the
intersection of subpools, we did not receive any information
about the models within a pool yet. Since we were interested in
the structure of the models, especially the wiring of Sorafenib and
crosstalk edges, we selected the classification analysis from the
pipeline. Here, we classified for the number of optional edges and
the presence of an optional edges. As a result, all models within
one class have the same interaction graph, thus only differ in
their logical functions (see tables in online repository). Looking at
these classes, we can state that for both specific pools there are no
rejected edges, since each edge appears in at least one model. This
also means that we cannot exclude any of the Sorafenib targets
for both cell lines. We can visualize these results by showing the
frequency of edges across a pool in Figure 5, where we define
the frequency of an edge as the number of models containing
this edge divided by the number of models in the pool. Here,
the graphs (A) and (B) for the full pools of each cell line show
differences in the frequency of the optional edges, especially in
the Sorafenib targets and the feedback. While in MZ1257RC
the frequency of Sora influences is high, in MZ1851RC they
are low especially for IGFR and EGFR. Moreover, one of the
objectives was to identify the effect of the mutation in mTOR on
the feedback in cell line MZ1851RC, where in Figure 5B 100% of
themodels in the pool Rp.1857 contain this feedback, while in the
other cell line this value only reaches 71%. Also we can observe
that every optional edge is present, since no edge is missing.
We can also restrict the classification to a subset of models,
e.g., shown in the Figures 5C,D. For cell line MZ1257RC, we
selected all models that contain an activating edge from Sorafenib
to Raf, where we can observe an enrichment in the crosstalk from
PI3K to Raf compared to the full pool (Figure 5C). In contrast,
if we filter for all models with an edge from Sora to EGFR in cell
line MZ1851RC (Figure 5D), the connection between Sora and
IGFR is lost, which means that there is no model containing both
edges. Moreover, the frequency of the connection between EGFR
and PI3K is reduced. However, since these effects are statistics
across a pool of models, it is hard to draw any conclusions about
single models.
3.4.3. Minimal Mechanisms for Sorafenib Targets
Although the classification analysis provides a good overview and
intuition about the cell line specific pools, the result shows that
a more detailed view can provide more information. Looking at
Frontiers in Physiology | www.frontiersin.org 10 October 2018 | Volume 9 | Article 1335
Thobe et al. Evaluating Uncertainty Using Model Pools
FIGURE 5 | Classification of specific pools for both cell lines, where the color of an optional edge gives the frequency in the respective subpool. In (A) all 1017 models
for cell line MZ1257RC are visualized and in (C) the subpool of 193 models that contain the edge from Sora to Raf is shown. In (B) all 293 model of cell line
MZ1851RC are presented and in (D) a subpool of 72 models with an edge from Sora to EGFR are shown.
theminimal structures or mechanisms of each pool, we wanted to
extract more information on how the crosstalk might be linked to
the Sorafenib mechanism. For this aim, we analyzed the cell line
specific pools for two features: the number of Sorafenib targets
and possible crosstalk mechanisms. Due to the large number of
models in the pools, we separated the pool for three scenarios: no
influence of Sorafenib, meaning that all three optional outgoing
edges of Sora are not present, Sorafenib has one target only,
Sorafenib has exactly two targets and Sorafenib has exactly
three targets. In Table 3, the minimal models according to these
scenarios for the pool Rp.1257 and in Table 4 for the pool
Rp.1851 are listed.
The specific pool for MZ1257RC shows that every
combination of Sorafenib target from none to all is present
in the pool, thus we cannot exclude any hypotheses in this
cell line (see Table 3). However, we can see that every model
contains at least one crosstalk edge and every edge appears in
a minimal model. For one Sora target, there is always a basic
crosstalk from the MAPK pathway to PI3K signaling either by
EGFR on PI3K or by Erk on mTORC1. For Raf, additionally
the crosstalk from PI3K on Raf becomes necessary, which we
already identified in Figure 5C. For dual targets in Table 3C,
IGFR/EGFR requires the cross-activation from EGFR on PI3K
or the feedback, IGFR/Raf require (PI3K,Raf) in combination
with any of the other crosstalk or the feedback and EGFR/Raf
needs (PI3K,Raf) and one crosstalk. In case all three targets are
affected by Sora, the (PI3K,Raf) edge and any of the crosstalks or
the feedback are required.
The minimal structures in the second cell line MZ1851RC
exclude two scenarios: IGFR/EGFR as dual targets (as shown in
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TABLE 3 | Minimal mechanisms for Sorafenib targets and crosstalk in Rp.1257.
Sorafenib
targets
(EGFR,
PI3K)
(Erk,
mTORC1)
(mTORC1,
IGFR)
(PI3K,
Raf)
(A) None 0 1 0 0
(B) IGFR 1 0 0 0
0 1 0 0
EGFR 1 0 0 0
0 1 0 0
Raf 1 0 0 1
0 1 0 1
(C) IGFR/EGFR 1 0 0 0
0 0 1 0
IGFR/Raf 1 0 0 1
0 0 1 1
0 1 0 1
EGFR/Raf 1 0 0 1
0 1 0 1
(D) All 1 0 0 1
0 0 1 1
0 1 0 1
Minimal models after classification of Rp.1257 for (A) no Sorafenib targets, (B) exactly one
target, (C) exactly two targets, and (D) all three possible targets are affected.
TABLE 4 | Minimal mechanisms for Sorafenib targets and crosstalk in Rp.1851.
Sorafenib
targets
(EGFR,
PI3K)
(Erk,
mTORC1)
(mTORC1,
IGFR)
(PI3K,
Raf)
(A) None 0 1 1 0
1 0 1 0
(B) IGFR 1 0 1 0
0 1 1 0
EGFR 1 0 1 0
0 1 1 0
Raf 1 0 1 1
0 1 1 1
(C) IGFR/EGFR
IGFR/Raf 0 1 1 1
1 0 1 1
EGFR/Raf 0 1 1 1
1 0 1 1
(D) All
Minimal models after classification of Rp.1851 for (A) no Sorafenib targets, (B) exactly one
target, (C) exactly two targets, and (D) all three possible targets are affected.
Figure 5D) and all three targets simultaneously. Table 4 shows
models in the pool that are not affected by Sorafenib. Compared
to cell line MZ1257RC, there are similarities and difference in
the model structures. Raf as a Sorafenib target again requires the
edge from PI3K on Raf to be present and also the models always
require a crosstalk from the MAPK pathway on PI3K signaling,
but additionally the feedback is essential for every model.
3.4.4. Interpretation of Analysis Results
The minimal models give an overview about how the system
could compensate the influence of the inhibitor to fit the data
for different levels of influence. For this aspect the cell lines
show similarities and differences in their model structures, where
two trends can be extracted from the minimal mechanisms.
First, all models require at least one crosstalk edge to be able to
produce trajectories that match the data we applied. Interestingly,
adding more Sorafenib targets most often does not enforce
more or different crosstalk edges, with the exception of Raf.
Within Rp.1851 the mechanisms for every Sorafenib target and
all combinations show the identical minimalmechanism, plus the
edge for Raf. A possible explanation for this observation could
be the symmetrical structure of the model, in particular when
the feedback is active as it is in every model of Rp.1851. Both
pathways consist of a cascade of activating edges with a negative
feedback on the Sorafenib target. It would be interesting to apply
data which breaks with this symmetry, e.g., with a PI3K inhibitor
to block the crosstalk.
The second clear trend we can identify from the results is
that Raf as Sora target requires the cross-activation from PI3K
on Raf. Since Raf is the designated Sorafenib target, this result
is interesting. Looking at the PKN structure and the data, we
can see that Erk becomes active under Sorafenib treatment and
the only activator for Erk is Raf. In the MAPK pathway, Raf
is activated by EGFR, which itself is inhibited by Erk. Thus, if
Erk should become and stay active over longer time periods as
shown in the data, Raf needs another activator to compensate the
inhibition through Sorafenib. However, Sorafenib was described
to have a paradoxical effect on the MAPK pathway. While, in
cell lines carrying a BRAF mutation the signaling was efficiently
blocked, cell lines with WT-BRAF showed an activation of
Erk (Hatzivassiliou et al., 2010; Heidorn et al., 2010; Poulikakos
et al., 2010). Thus, further investigations are necessary to exploit
whether this observation is an artifact of the model or has
biological relevance. In detail, paradoxical activation by Sorafenib
and the role the crosstalk from PI3K to Raf would need to be
examined, which would require a refined model where the edge
from Sorafenib on Raf could also be activating and more data,
e.g., an experiment with a PI3K inhibitor would be interesting in
this context.
3.4.4.1. Overlap of Sorafenib targets
Another general question is, whether we assume Sorafenib to
have the same targets in both cell lines. One could argue that
the cell lines could differ in their internal wiring meaning
the crosstalk, but the biochemical targets of Sorafenib should
be independent of cell lines. Assuming that all three targets,
IGFR, EGFR, and Raf, are expressed in both cell lines, the
intersection of the results in Tables 3, 4 would further narrow
down possible targets. In that case, we could exclude the case
of Sorafenib affecting all targets simultaneously, since in cell
line MZ1851RC there are no models that have IGFR, EGFR,
and Raf as targets. Moreover, the combination IGFR/EGFR is
not present in Rp.1851, thus either Sorafenib targets either one
of the receptors by themselves or additionally Raf in these cell
lines. Even though these results are not clear, they can support
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and guide further studies, especially experiments where receptors
are stimulated additionally to the drug treatment would be
beneficial.
3.4.4.2. Models without Sorafenib targets
A surprising result of the analysis is the presence of models
without a Sorafenib target. In cell line MZ1257RC, <1% of the
models have no Sorafenib target, while the pool for MZ1851RC
16% of the models fall into this category. Since the data
clearly shows an effect of the drug on components in this
pathway, we expected all models to have at least one target
of Sorafenib to be influenced. Thus, the data set from cell
line MZ1851RC seems to be not restrictive enough for every
model to require an interaction from Sorafenib. Since only a
subset of components is measured, some models can match
the data by specific initial states. Here, additional data would
be beneficial to refine the results, especially measuring more
components would reduce the degree of freedom for fitting the
data.
4. DISCUSSION
In this paper, we present an alternative approach to standard
modeling procedures. Instead of building and validating one
model, we incorporate uncertain information or hypotheses to
build a pool of models that is then filtered for data and analyzed
using specific strategies. An advantage of this method is that we
can test multiple hypotheses at the same time, but it comes at the
cost of high complexity and challenging analysis. For this reason,
we created a pipeline with specifically defined objectives and
analysis templates that the modeler can select and combine. In
addition to templates for objectives, data formalization and pool
analysis presented in previous work (Thobe et al., 2014, 2017;
Streck et al., 2015), we introduce two new objectives, namely
finding driver mutations and drug testing, as well as two analysis
options, namely classification and minimal models.
In the second part of the paper, the pipeline is applied to
study the uncertain wiring and effect of a drug in cancer cells
based on a rich data set. Two RCC cell lines, MZ1257RC and
MZ1851RC, were observed to behave differently upon Sorafenib
treatment, thus we tested possible drug targets in the MAPK and
PI3K signaling and also investigated possible crosstalk between
these pathways in a cell line specific manner, incorporating
a mutation with uncertain effect as objectives. As a result, a
substantial reduction from 19,404 for the initial pool to 1,017
for MZ1257RC and 293 for MZ1851RC was observable, and the
empty intersection of both pools shows that the cell line specific
models indeed have a different wiring. In order to cope with
the complexity of having hundreds of models as outcome of the
study, we developed different analysis tools. Here, we showed that
classification of the pool can provide an overview on the models
in the pool and give information on essential or neglected edges.
In the case study, the classification showed that the feedback from
mTORC1 on IGFR was active in both cell lines. We had set this
edge to optional since the cell line MZ1851RC carries a mutation
in mTOR and we hypothesized that this affects the feedback. As
a result, all models in Rp.1851 show the feedback in their models
and thus the mutation does not affect the function of mTORC1
toward IGFR. However, for cell line MZ1257RC, which does not
carry a mutation in mTOR, only 71% of the models in the pool
contain this edge. An explanation for this could be that we had
to exclude the data for IGFR in the Bioplex experiment, since
the variance of the data was too low to allow for a meaningful
discretization, which could also be the reason for the largermodel
pool in comparison to MZ1851RC.
For the crosstalk and the Sorafenib mode of action the
classification analysis showed no clear trend, since the results
are complex and hard to interpret. For this reason, we listed the
minimal models according to the number of Sorafenib targets
and the required crosstalk to gain more detailed information
on the simplest solution (Tables 3, 4). Even though we cannot
exclude any Sorafenib target and crosstalk in the analysis, we
are able to identify patterns, where specific Sorafenib targets
require different crosstalk edges to be present, e.g., Raf requires
a crosstalk from PI3K on Raf. Another important observation
from the classification was that there are models in the pools of
both cell lines without any interaction between Sorafenib and
its target. The conclusion from this result is that the data was
not restrictive enough to exclude these models and further data
is necessary resolve this issue. However, in case we would only
fit one model to the data, we would have missed this lack of
expressiveness.
The strength of underlying approach is based on its paradigm
of considering possibly huge sets of models for testing and
comparison. Consequently, it does not scale as well as single
model approaches. The software utilized here is limited by its
model checking tool NuSMV, where more than 50 components
are not solvable within reasonable time. For the analysis
presented in this paper, the program was run on a Ubuntu
17.10 workstation with a processor i7-7700, 3.6 GHz, and 32GB
RAM. The script with 10 components took 143 minutes in
TomClass, which included building the pool, model-checking,
and classification of 19,404 models. Tools like caspo list running
times of approximately 56 mins for models of size 45 generating
a model pool with 384 models and thus can still handle medium
sized models (Videla et al., 2017). The software Tremppi was
shown to be able to handle a model pool of size 259,200 and
perform model-checking of 40 data sets within 151–177 min
depending on parameter settings on a similar workstation (Streck
et al., 2016). In general, the kind of models that are feasible for
this approach are a trade-off between number of components and
number of uncertain edges, the latter of which affects the size of
the model pool. This approach aims at exploring uncertainties in
small to medium sized models, which is well-suited to represent
interesting processes such as signaling pathways and regulatory
modules.
While the generation and especially model-checking process
is computationally expensive, the analysis and interpretation
of these pools, which in our case are just large tables, is
challenging from a biological perspective. Thus we propose
to define clear objectives for designing the study as well as
offer different analysis strategies to extract new information
from the complex results. There are many possibilities for
extensions especially one could think of further biologically
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interesting objectives, but also including different kind of data
and more analysis options such as algorithms to find special
patterns. Moreover, we are not limited to the Boolean set-
up, but are able to handle multivalued models (Streck et al.,
2015). Finally, although the pipeline was developed for signaling
networks, the approach can be applied to any related modeling
problem.
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